2,641 results match your criteria Chorioretinopathy Central Serous


Comment on "Clinical Factors Related to Loculation of Fluid in Central Serous Chorioretinopathy".

Am J Ophthalmol 2022 Jun 21. Epub 2022 Jun 21.

Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

View Article and Full-Text PDF

Reply to the Comment on Clinical Factors Related to Loculation of Fluid in Central Serous Chorioretinopathy.

Am J Ophthalmol 2022 Jun 21. Epub 2022 Jun 21.

Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address:

View Article and Full-Text PDF

Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy.

J Clin Med 2022 Jun 13;11(12). Epub 2022 Jun 13.

Department of Ophthalmology, Ajou University School of Medicine, Suwon 16499, Korea.

We evaluated the effect of intravitreal bevacizumab injection (IVB) on choroidal thickness, and studied its association with the therapeutic response in chronic central serous chorioretinopathy (CSC). The clinical features of 78 eyes with chronic CSC treated with IVB from October 2014 to June 2020 were retrospectively evaluated. Visual acuity (VA), central retinal thickness (CRT), and sub-foveal choroidal thickness (SFCT) were analyzed at baseline, 1 month following initial IVB, and the last follow-up examination. Read More

View Article and Full-Text PDF

Distinct characteristics of central serous chorioretinopathy according to gender.

Sci Rep 2022 Jun 22;12(1):10565. Epub 2022 Jun 22.

Department of Ophthalmology, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan.

To investigate the differences in clinical and genetic characteristics between males and females with central serous chorioretinopathy (CSC). Consecutive 302 patients (mean age; 56.3 ± 11. Read More

View Article and Full-Text PDF

Case series: pachychoroid pigment epitheliopathy transformed to polypoidal choroidal vasculopathy after long-term follow-up.

BMC Ophthalmol 2022 Jun 21;22(1):272. Epub 2022 Jun 21.

Department of Ophthalmology, Peking University People's Hospital, No.11 Xizhimen South Street, Beijing, 100044, China.

Background: Pachychoroid pigment epitheliopathy (PPE), a retinal disorder that falls into the pachychoroid spectrum, is characterized by retinal pigment epithelium changes in pachychoroid eyes without existing or previous subretinal fluid or soft drusen. Previous reports have indicated that PPE may share some pathophysiologic component with other pachychoroid spectrum diseases and could transform into central serous chorioretinopathy (CSC) during follow-up. CSC transformation to PNV and PCV has also been reported, but PPE transformation to PCV has not been reported. Read More

View Article and Full-Text PDF

INNER AND OUTER CHOROIDAL CHANGES IN THE FELLOW EYE OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY.

Retina 2022 07;42(7):1238-1247

Ophthalmology Department, San Raffaele University Hospital, Milan, Italy; and.

Purpose: To quantitatively evaluate the inner and outer choroidal changes in the fellow eyes of patients with unilateral central serous chorioretinopathy (CSC).

Methods: We analyzed data from patients with a diagnosis of unilateral CSC who had structural optical coherence tomography (OCT) and swept-source OCT angiography obtained. An additional group of age-matched healthy patients was included for comparison. Read More

View Article and Full-Text PDF

Volumetric quantification of choroid and Haller's sublayer using OCT scans: An accurate and unified approach based on stratified smoothing.

Comput Med Imaging Graph 2022 Jun 2;99:102086. Epub 2022 Jun 2.

Dept. of Electrical Engg, Indian Institute of Technology Hyderabad, Telangana, India.

Background And Objective: The choroid, a dense vascular structure in the posterior segment of the eye, maintains the health of the retina by supplying oxygen and nutrients, and assumes clinical significance in screening ocular diseases including age-related macular degeneration (AMD) and central serous chorioretinopathy (CSCR). As a technological assist, algorithmic estimation of choroidal biomarkers has been suggested based on sectional (B-scan) optical coherence tomography (OCT) images. However, most such 2D estimation techniques are compute-intensive, yet enjoy limited accuracy and have only been validated on OCT image datasets of healthy eyes. Read More

View Article and Full-Text PDF

Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy.

Clin Ophthalmol 2022 9;16:1871-1882. Epub 2022 Jun 9.

Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, 10400, Thailand.

Purpose: Patients with hypercortisolism have been associated with a higher prevalence of the pachychoroid spectrum including central serous chorioretinopathy (CSCR), which may explain the inconsistency of therapeutic responses of the mineralocorticoid receptor antagonist because hyperaldosteronism has rarely been detected in patients with CSCR. Therefore, this study aimed to evaluate the effects of ketoconazole, the first-line cortisol inhibitor, on the resolution of subretinal fluid (SRF) in CSCR and to analyze correlations between choroidal thickness and steroid hormones.

Patients And Methods: This retrospective cohort study included 41 naïve CSCR eyes of 41 patients categorized into control (20 eyes) and treatment (21 eyes) groups. Read More

View Article and Full-Text PDF

Utility of an additional photodynamic therapy after multiple failed of this treatment in chronic central serous chorioretinopathyUtility of PDT after previous failures in CSC.

Photodiagnosis Photodyn Ther 2022 Jun 8:102953. Epub 2022 Jun 8.

Department of Ophthalmology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria (IdISSC), Madrid, Spain.

Purpose: To assess the efficacy of an additional photodynamic therapy (PDT) in chronic central serous chorioretinopathy (cCSCR) patients who have two or more previous failed PDTs.

Methods: Ten eyes of 10 patients with cCSCR who had received two or more PDTs without complete resolution of the subretinal fluid (SRF) or with early recurrence (before 3 months) were included. An additional half-fluence PDT was performed. Read More

View Article and Full-Text PDF

Photodynamic Therapy with Chlorin e6 Derivative for Chronic Central Serous Chorioretinopathy (Pilot Study).

J Ocul Pharmacol Ther 2022 Jun 10. Epub 2022 Jun 10.

The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine, Odesa, Ukraine.

To evaluate the use of photodynamic therapy (PDT) with chlorin e6 (Ce6) derivative in patients with chronic central serous chorioretinopathy (CSC). Participants in this interventional, single-center clinical pilot study included 39 patients (39 eyes) with chronic CSC. Primary objectives were to assess safety and change in decimal best-corrected visual acuity (BCVA) during the 12-month follow-up. Read More

View Article and Full-Text PDF

Characterization of Choroidal Morphology and Vasculature in the Phenotype of Pachychoroid Diseases by Swept-Source OCT and OCTA.

J Clin Med 2022 Jun 6;11(11). Epub 2022 Jun 6.

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

The objective of this study was to characterize the choroidal morphology and vasculature in pachychoroid diseases (PCD). A total of 49 eyes with polypoidal choroidal vasculopathy (PCV), 43 eyes with neovascular age-related macular degeneration (nAMD), and 50 eyes with central serous chorioretinopathy (CSC), along with 80 healthy eyes, were enrolled in this nested case-control study. The swept-source optical coherent tomography (OCT), OCT angiography, and En face images were quantitatively analyzed. Read More

View Article and Full-Text PDF

Accommodation is Decreased in Eyes with Acute Central Serous Chorioretinopathy.

Optom Vis Sci 2022 Jun 9. Epub 2022 Jun 9.

Department of Ophthalmology, Military Medical Academy, St Petersburg, Russia (DSM, ANK, ASV), and University of Pittsburgh, UPMC Eye Center, Pittsburgh, Pennsylvania (JC).

Significance: This is a case-control study showing changes in accommodation in eyes with acute central serous chorioretinopathy. Decreased accommodative amplitude we found in affected eyes may indicate suppression of parasympathetic activity in those eyes as one of the pathophysiological mechanisms controlling choroidal thickness and perfusion.

Purpose: To evaluate the changes of accommodation in patients with acute central serous chorioretinopathy (CSC). Read More

View Article and Full-Text PDF

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses.

Int J Retina Vitreous 2022 Jun 7;8(1):34. Epub 2022 Jun 7.

Postgraduate Program in Health Sciences, IAMSPE and Laboratory of Medical Investigation 51 (LIM-51), University of São Paulo, São Paulo, Brazil.

Background: Mineralocorticoid receptor antagonists (MRAs) are widely used for chronic central serous chorioretinopathy (cCSCR), but their effectiveness remains unclear. This research was conducted to evaluate the efficacy of this drugs for cCSCR.

Methods: This is a review of randomized clinical trials (RCT) comparing MRAs to placebo in adults with cCSCR, using the effects of MRAs on best-corrected visual acuity (BCVA) and adverse events as primary outcomes and the effects of MRAs on anatomical parameters as secondary outcomes: central subfield thickness (CST), subretinal fluid height (SFH) and central choroidal thickness (CCT). Read More

View Article and Full-Text PDF

OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.

BMC Ophthalmol 2022 Jun 7;22(1):252. Epub 2022 Jun 7.

Eye Center, Second Affiliated Hospital, College of Medicine, Zhejiang University, No.88, Jiefang Road, Hangzhou, 310009, China.

Background: To identify the OCT biomarkers related to the anatomical outcomes in eyes with central serous chorioretinopathy (CSCR) after subthreshold micropulse laser (SML) treatment.

Methods: Patients with CSCR underwent SML were enrolled in this retrospective study. Only patients who underwent enhanced depth imaging optical coherence tomography (EDI-OCT) examination before and after SML were selected. Read More

View Article and Full-Text PDF

Predicting retinal sensitivity using optical coherence tomography parameters in central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol 2022 Jun 4. Epub 2022 Jun 4.

Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Purpose: To predict changes in retinal sensitivity using optical coherence tomography (OCT) in eyes with central serous chorioretinopathy (CSC).

Methods: Twenty-three eyes in 23 patients with CSC were enrolled. Retinal sensitivity was measured twice using microperimetry in all the examined eyes. Read More

View Article and Full-Text PDF

Steroid-induced central serous chorioretinopathy in neuromyelitis optica spectrum disorders: a case report.

Neurol Sci 2022 Jun 4. Epub 2022 Jun 4.

Department of Neurology, Third Affiliated Hospital of Sun Yat-sen University, NO. 600, Tianhe Road, Tianhe District, Guangzhou, CN 510630, Guangdong, China.

View Article and Full-Text PDF

Predicting persistent central serous chorioretinopathy using multiple optical coherence tomographic images by deep learning.

Sci Rep 2022 Jun 4;12(1):9335. Epub 2022 Jun 4.

Department of Ophthalmology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, #327 Sosa-ro, Wonmi-gu, Bucheon, Gyeonggi-do, 14647, Republic of Korea.

We sought to predict whether central serous chorioretinopathy (CSC) will persist after 6 months using multiple optical coherence tomography (OCT) images by deep convolutional neural network (CNN). This was a multicenter, retrospective, cohort study. Multiple OCT images, including B-scan and en face images of retinal thickness (RT), mid-retina, ellipsoid zone (EZ) layer, and choroidal layer, were collected from 832 eyes of 832 CSC patients (593 self-resolving and 239 persistent). Read More

View Article and Full-Text PDF

Acute Unilateral Central Serous Chorioretinopathy after Immunization with Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Literature Review.

Semin Ophthalmol 2022 Jun 3:1-9. Epub 2022 Jun 3.

Department of Ophthalmology, Parke Street Specialist Centre, Katoomba, NSW, Australia.

Introduction: A 43-year-old Caucasian male presented to our ophthalmology clinic with blurry vision and metamorphopsia in his right eye, 24 hours after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine.

Methods: Clinical examination and imaging tests were consistent with acute unilateral central serous chorioretinopathy (CSCR) that completely resolved after 2 months without any treatment. He had no significant ophthalmic or medical history. Read More

View Article and Full-Text PDF

Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases.

Sci Rep 2022 Jun 1;12(1):9105. Epub 2022 Jun 1.

Department of Ophthalmology and Visual Science, Osaka City University Graduate School of Medicine, Osaka, 545-8585, Japan.

The purpose of this study was to investigate the occurrence rate and predictors of photodynamic therapy (PDT) induced acute exudative maculopathy (PAEM). This retrospective study included 39 eyes of 39 patients (32 males and 7 females), who were treated with initial PDT. PAEM was defined as an increase in central retinal thickness (CRT) of 15% or more measured by OCT on day 3 after PDT compared with baseline. Read More

View Article and Full-Text PDF

Efficacy of Subthreshold Micropulse Laser for Chronic Central Serous Chorioretinopathy: A Meta-Analysis.

Photodiagnosis Photodyn Ther 2022 May 27:102931. Epub 2022 May 27.

Aier Eye Hospital of Wuhan University, Wuhan, 430050, China. Electronic address:

Purpose: To evaluate the efficacy of subthreshold micropulse laser (SML) treatment for chronic central serous chorioretinopathy (CSC).

Methods: PubMed, Cochrane Library, and Embase were comprehensively searched for studies published up to April 19, 2021. Randomized controlled trials (RCTs), retrospective and prospective cohort studies that compared SML with any other intervention for chronic CSC were selected. Read More

View Article and Full-Text PDF

A multicentre study of the risk factors associated with recurrence of central serous chorioretinopathy.

Acta Ophthalmol 2022 May 28. Epub 2022 May 28.

Department of Ophthalmology, Hyogo College of Medicine, Hyogo, Japan.

Purpose: To investigate potential clinical and multimodal imaging factors in central serous chorioretinopathy (CSC) recurrence.

Methods: The study was performed at nine Japanese medical institutions for patients who had experienced an active CSC episode. Demographic data and medical history were reviewed retrospectively. Read More

View Article and Full-Text PDF

Visual function during and after an acute central serous chorioretinopathy episode.

Doc Ophthalmol 2022 May 24. Epub 2022 May 24.

Eye Hospital, University Medical Centre Ljubljana, 1000, Ljubljana, Slovenia.

Purpose: To evaluate visual function parameters during and after an acute central serous chorioretinopathy (CSC) episode.

Methods: A prospective study included 19 fovea involving acute CSC patients with episode resolution within 3 months from the episode onset. Optical coherence tomography, best corrected visual acuity (BCVA), contrast sensitivity (CS), microperimetry (MP), and multifocal electroretinography (mfERG) were performed at baseline, 3 and 6 months from the episode onset. Read More

View Article and Full-Text PDF

Subretinal fluid accumulation in a patient with polycythemia vera after receiving a prostaglandin I2 analogue treatment.

Am J Ophthalmol Case Rep 2022 Sep 4;27:101568. Epub 2022 May 4.

Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Purpose: To report a case of polycythemia vera (PV) with subretinal fluid accumulation after the administration of prostaglandin I2 (PGI2) analogue.

Observations: A 57-year-old woman diagnosed as having PV was referred to our department for the evaluation of severe metamorphopsia in the left eye, which gradually progressed after the initiation of oral administration of PGI2 mimetics. At the first visit, the patient's best-corrected visual acuities (BCVAs) were 20/20 OD and 20/30 OS. Read More

View Article and Full-Text PDF
September 2022

Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine.

J Fr Ophtalmol 2022 Jun 28;45(6):603-607. Epub 2022 Apr 28.

Beirut Eye and ENT Specialist Hospital, Beirut, Lebanon; Beirut Eye Clinic, Beirut, Lebanon.

We present a case of acute bilateral multifocal CSCR in a young healthy Caucasian female occurring 3 days after receiving the first dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The true incidence of this adverse reaction might be underreported in asymptomatic unilateral or paracentral cases. We believe that the post-COVID-19 vaccination occurrence of CSCR is not a sufficient reason to withhold the second dose of the vaccine. Read More

View Article and Full-Text PDF

Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy.

Eye (Lond) 2022 May 19. Epub 2022 May 19.

Institute of Ophthalmology, University of Modena and Reggio Emilia, Modena, Italy.

Background: To investigate choroidal vascularity index (CVI) changes after oral eplerenone treatment in chronic central serous chorioretinopathy (cCSC) using the Spectral-domain (SD)-Optical Coherence Tomography (OCT) with enhanced depth imaging (EDI) mode.

Methods: Thirty-six eyes of 18 patients suffering from cCSC with monolateral foveal subretinal fluid (FSRF) successfully treated with oral eplerenone treatment and 18 age-matched healthy subjects were enroled in this retrospective study. EDI-OCT images obtained using Heidelberg Spectralis OCT device in patients with cCSC and FSRF (group 1); fellow eye (group 2) or healthy patients (healthy) were exported and then imported into image analysis ImageJ software for subsequent quantitative analysis. Read More

View Article and Full-Text PDF

Blue-light fundus autofluorescence imaging of pigment epithelial detachments.

Eye (Lond) 2022 May 17. Epub 2022 May 17.

Department of Ophthalmology, University of Bonn, Bonn, Germany.

Background: Pigment epithelial detachments (PEDs) occur in association with various chorioretinal diseases. With respect to the broad clinical spectrum of PEDs we describe fundus autofluorescence (FAF) characteristics of PEDs.

Methods: Ninety-three eyes of 66 patients (mean age 71. Read More

View Article and Full-Text PDF

Long term results of three anti-vascular endothelial growth factor agents in pachychoroid neovasculopathy.

Cutan Ocul Toxicol 2022 May 30:1-10. Epub 2022 May 30.

Department of Ophthalmology, School of Medicine, Acibadem University, Istanbul, Turkey.

Purpose: To assess morphological changes and visual results in eyes with pachychoroid neovasculopathy (PNV) that underwent different intravitreal anti-vascular endothelial growth factor (VEGF) agents.

Materials And Methods: This is a retrospective, observational, comparative study that included 76 PNV eyes in 76 patients that were allocated to three groups according to the monotherapy injection procedure, as follows: the intravitreal bevacizumab (IVB) group, intravitreal ranibizumab (IVR) group, and intravitreal aflibercept (IVA) group. Central macular thickness (CMT), best-corrected visual acuity (BCVA), and subfoveal choroidal thickness (SFCT) were measured at baseline, after treatment 1st month, 3rd month, 6th month, and 12th month, and at the final post-treatment examination. Read More

View Article and Full-Text PDF